Recursion Pharmaceuticals is gearing up for multiple Phase 2 clinical trial readouts, beginning in Q3 2024, while also advancing its technological infrastructure for drug discovery. The company's CEO, Chris Gibson, highlighted the potential for near-term value catalysts, including clinical trial results and new partnerships, emphasizing the growing recognition of combining large-scale computing with proprietary data generation.
Clinical Pipeline Updates
Cerebral Cavernous Malformation (CCM): The Phase 2 SYCAMORE trial of REC-994, a randomized, double-blind, placebo-controlled study, has fully enrolled 62 participants. The primary endpoint focuses on safety and tolerability, with secondary endpoints assessing clinician-measured outcomes, lesion imaging, patient-reported outcomes, and biomarkers. Data readout is expected in Q3 2024.
Neurofibromatosis Type 2 (NF2): The adaptive Phase 2/3 POPLAR trial of REC-2282 is ongoing, exploring two doses in adults and adolescents with progressive NF2-mutated meningiomas. Adult enrollment is expected to complete in Q2 2024, with preliminary Phase 2 safety and efficacy data anticipated in Q4 2024.
Familial Adenomatous Polyposis (FAP) and AXIN1/APC Mutant Cancers: Phase 2 data for REC-4881 in FAP and AXIN1/APC mutant cancers are expected in H1 2025. The TUPELO trial (FAP) is an open-label, multicenter study, while the LILAC trial (AXIN1/APC) has enrolled multiple participants since its initiation in late 2023.
[object Object], Infection: REC-3964, a first-in-class C. difficile toxin inhibitor, demonstrated superiority versus bezlotoxumab in preclinical models. Phase 1 data will be presented at the World Congress on Infectious Diseases in June 2024, with a Phase 2 study in high-risk patients planned for 2024.
Advanced HR-Proficient Cancers: An IND submission for a lead candidate targeting RBM39 is expected in H2 2024, with a Phase 1 trial planned for relapsed/refractory cancer. The primary endpoint will be safety and tolerability, with secondary endpoints exploring pharmacokinetics and anti-tumor activity.
Platform and Technology Advancements
Recursion is expanding its supercomputing capabilities with BioHive-2, powered by NVIDIA H100 GPUs. Performance benchmarking is underway, and the company believes it may rank among the top 50 supercomputers globally. This infrastructure supports the construction of foundation models across biology, chemistry, and patient outcomes.
The company has also scaled its transcriptomics technology, sequencing over 1 million transcriptomes. Recursion is advancing the development of a whole-genome knockout transcriptomics map, expected to be completed in the coming quarters.
Strategic Partnerships
A multi-year agreement with Helix grants Recursion access to hundreds of thousands of de-identified records, including genomic data and longitudinal health records. This data will be used to train causal AI models and design biomarker and patient stratification strategies.
Ongoing collaborations with Bayer (undruggable oncology) and Roche-Genentech (neuroscience and gastrointestinal oncology) continue to advance, with potential for option exercises related to partnership programs and data sharing.
